Global assessment of partial artemisinin resistance: multicenter trial across Kenya, Peru, and Thailand in patients with uncomplicated Plasmodium falciparum malaria.

ABSTRACT:

Objectives

Artemisinin-resistant Plasmodium falciparum challenges the effectiveness of all artemisinin-based combination therapies.

Methods

We conducted a clinical study in Peru, Kenya, and Thailand between June 2013 and November 2015 in subjects treated with three standard doses of artesunate followed by two doses of mefloquine. The primary endpoint was parasite clearance half-life (PC_1/2) during the 72-hour period of treatment. Secondary endpoints included clinical outcome at 42 days, detection of kelch13 (K13) mutations, pharmacokinetics, and pharmacodynamics.

Results

The mean PC_1/2 was higher in the Thai (4.1 hours) than Peruvian (2 hours) or Kenyan cohorts (2.2 hours) (P <0.0001). Higher PC_1/2 was partially explained by K13 mutati

SUBMITTER: Andagalu B 

PROVIDER: S-EPMC12410058 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature